Rapt Therapeutics Inc (RAPT)

$30.14 +1.04 (3.57%)
Market Cap 498.46M
Revenue (ttm) 0.00
Net Income (ttm) -129.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 532,600
Avg Vol 171,918
Day's Range N/A - N/A
Shares Out 16.54M
Stochastic %K 86%
Beta 0.23
Analysts Sell
Price Target $25.83

Company Profile

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its l...

Industry: Biotechnology
Sector: Healthcare
Phone: 650-489-9000
Address:
561 Eccles Avenue, South San Francisco, United States
steadyhandswin
steadyhandswin Oct. 4 at 3:28 AM
$RAPT place is pretty quiet considering the price movement lately. Full steam ahead !
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:29 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $IBKR $SNSE $RAPT $FGEN
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:40 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $CRCL $RIOT $RAPT $CRL
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:34 AM
retail running ASTC now! the ASTC Float only 400k could squeeze hard wow $BNRG $IBKR $SNSE $RAPT "
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:35 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $RAPT $FGEN $SMX $SHPH 🔥
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 1 at 7:52 PM
$GDRX 4%[22%] $FRMI 3%[45%] $VSA -3%[-11%] $ABVE 3%[22%] $RAPT -3%[5%] most notable movement into the final minutes of trading.
0 · Reply
SweepCastApp
SweepCastApp Sep. 30 at 10:36 PM
$RAPT: Unusual Options Activity Alerted CALL flow observed 181x contracts at Strike price of $25 Exp on 02/20/2026 with Premium of $148K and showing BULLISH Sentiment
0 · Reply
steadyhandswin
steadyhandswin Sep. 30 at 2:04 PM
$RAPT They're gonna try and walk it back down
1 · Reply
JarvisFlow
JarvisFlow Sep. 30 at 12:27 PM
Clear Street has updated their rating for RAPT Therapeutics ( $RAPT ) to Buy with a price target of 41.
0 · Reply
highnihilism
highnihilism Sep. 29 at 11:26 PM
$EBAY: 2.5K trades, $1.4M vs $2.6M avg (0.54x). Bullish skew: $1.0M calls/$399K puts. 93% single-leg. $SEZL: 788 trades, $1.4M vs $4.9M avg (0.27x). Bullish skew: $993K calls/$352K puts. 88% single-leg. $GT: 5.3K trades, $1.3M vs $286K avg (4.73x). Bullish skew: $988K calls/$364K puts. 51% single-leg. $RAPT: 122 trades, $1.0M vs $7.9K avg (130.5x). Bullish skew: $989K calls/$38K puts. 100% single-leg.
0 · Reply
Latest News on RAPT
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

Sep 29, 2025, 5:00 AM EDT - 5 days ago

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 2 months ago

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

Jun 23, 2025, 8:00 AM EDT - 3 months ago

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

Jun 13, 2025, 9:00 AM EDT - 4 months ago

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

RAPT Therapeutics to Participate in Upcoming Investor Conferences

Jun 4, 2025, 4:05 PM EDT - 4 months ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025, 8:00 AM EDT - 5 months ago

RAPT Therapeutics Reports First Quarter 2025 Financial Results

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

Apr 15, 2025, 8:00 AM EDT - 6 months ago

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 8:00 AM EST - 7 months ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 9 months ago

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

Jan 6, 2025, 8:00 AM EST - 9 months ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

RAPT Therapeutics Announces $150 Million Private Placement

Dec 23, 2024, 7:10 AM EST - 10 months ago

RAPT Therapeutics Announces $150 Million Private Placement

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

Nov 11, 2024, 10:34 AM EST - 11 months ago

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24, 2024, 6:32 PM EDT - 1 year ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

May 21, 2024, 8:39 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX SAGE TMCI

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20, 2024, 4:35 AM EDT - 1 year ago

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

RAPT Therapeutics Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 1 year ago

RAPT Therapeutics Reports First Quarter 2024 Financial Results

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Apr 9, 2024, 12:00 PM EDT - 1 year ago

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

VKTX, JANX and these biotech stocks are surging in 2024

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX MCRB RVNC

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 26, 2024, 4:00 AM EST - 1 year ago

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

Feb 20, 2024, 8:36 AM EST - 1 year ago

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:41 AM EST - 1 year ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

Feb 20, 2024, 7:30 AM EST - 1 year ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

Feb 13, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Nov 27, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

Nov 3, 2023, 12:00 PM EDT - 2 years ago

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

Nov 1, 2023, 4:05 PM EDT - 2 years ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Oct 18, 2023, 9:00 AM EDT - 2 years ago

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

Aug 30, 2023, 4:05 PM EDT - 2 years ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

Aug 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

RAPT Therapeutics: Major Catalysts Are A Long Way Off

Jun 13, 2023, 3:59 PM EDT - 2 years ago

RAPT Therapeutics: Major Catalysts Are A Long Way Off

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

Jun 7, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

May 25, 2023, 5:00 PM EDT - 2 years ago

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

May 3, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 4:19 PM EDT - 2 years ago

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

RAPT Therapeutics: Potential Strong Upside Ahead

Mar 30, 2023, 12:12 AM EDT - 2 years ago

RAPT Therapeutics: Potential Strong Upside Ahead

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

Mar 29, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

Mar 14, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Feb 7, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

Dec 8, 2022, 6:30 AM EST - 3 years ago

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

Nov 30, 2022, 7:05 PM EST - 3 years ago

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

steadyhandswin
steadyhandswin Oct. 4 at 3:28 AM
$RAPT place is pretty quiet considering the price movement lately. Full steam ahead !
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:29 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $IBKR $SNSE $RAPT $FGEN
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:40 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $CRCL $RIOT $RAPT $CRL
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:34 AM
retail running ASTC now! the ASTC Float only 400k could squeeze hard wow $BNRG $IBKR $SNSE $RAPT "
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:35 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $RAPT $FGEN $SMX $SHPH 🔥
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 1 at 7:52 PM
$GDRX 4%[22%] $FRMI 3%[45%] $VSA -3%[-11%] $ABVE 3%[22%] $RAPT -3%[5%] most notable movement into the final minutes of trading.
0 · Reply
SweepCastApp
SweepCastApp Sep. 30 at 10:36 PM
$RAPT: Unusual Options Activity Alerted CALL flow observed 181x contracts at Strike price of $25 Exp on 02/20/2026 with Premium of $148K and showing BULLISH Sentiment
0 · Reply
steadyhandswin
steadyhandswin Sep. 30 at 2:04 PM
$RAPT They're gonna try and walk it back down
1 · Reply
JarvisFlow
JarvisFlow Sep. 30 at 12:27 PM
Clear Street has updated their rating for RAPT Therapeutics ( $RAPT ) to Buy with a price target of 41.
0 · Reply
highnihilism
highnihilism Sep. 29 at 11:26 PM
$EBAY: 2.5K trades, $1.4M vs $2.6M avg (0.54x). Bullish skew: $1.0M calls/$399K puts. 93% single-leg. $SEZL: 788 trades, $1.4M vs $4.9M avg (0.27x). Bullish skew: $993K calls/$352K puts. 88% single-leg. $GT: 5.3K trades, $1.3M vs $286K avg (4.73x). Bullish skew: $988K calls/$364K puts. 51% single-leg. $RAPT: 122 trades, $1.0M vs $7.9K avg (130.5x). Bullish skew: $989K calls/$38K puts. 100% single-leg.
0 · Reply
steadyhandswin
steadyhandswin Sep. 29 at 8:36 PM
$RAPT well that was a lackluster day.
0 · Reply
highnihilism
highnihilism Sep. 29 at 4:57 PM
$RAPT 67 trades, $440K vs $7.9K avg (56x). $408K calls/$32K puts. 100% single-leg. Rapt Therapeutics bullish positioning.
0 · Reply
highnihilism
highnihilism Sep. 29 at 3:45 PM
$RAPT Rapt Therapeutics — 58 trades, $426K vs $7.9K avg (54x). Flow $408.5K calls vs $18K puts. 100% single-leg.
0 · Reply
Moon_Man25
Moon_Man25 Sep. 29 at 3:35 PM
$ANGX $CTMX $LGMK $NVNI $RAPT
0 · Reply
ximenaturner
ximenaturner Sep. 29 at 1:28 PM
$RAPT NXXT traders eye serial catalysts site build outs hookups power on events each one a headline and volume magnet into resistance breaks.
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 29 at 12:29 PM
$RAPT (+5.4% pre) RAPT Therapeutics (RAPT) Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy https://ooc.bz/l/78697
0 · Reply
notreload_ai
notreload_ai Sep. 29 at 11:25 AM
FDA OKs major trial (prestIgE) for $RAPT RPT904, a next-gen anti-IgE drug. It will treat ~100 people allergic to peanut, milk, or egg. The goal is a better, safe therapeutic option by blocking IgE, the key driver of these allergies. https://notreload.xyz/fda-greenlights-rapt-next-gen-food-allergy-treatment-trial/
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 29 at 10:43 AM
WATCHLIST SEP 29 2025 $VST Vistra To Triple Permian Basin Power Plant Capacity With $1B Gas Expansion In Texas, Greenlights Two New Gas Units $BW Babcock & Wilcox Receives Initial $10M Order As Part Of $40M Award To Supply Low-Pressure Wet Gas Scrubbing Technology For Installation At Petroleum Refinery In Canada $ENTA Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults $GSK GSK Appoints Luke Miels As CEO Designate For GSK. He Will Assume Full Responsibilities As CEO And Join The Board On 1 January 2026, Succeeding Current CEO, Dame Emma Walmsley $RAPT RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
0 · Reply
G101SPM
G101SPM Sep. 29 at 9:52 AM
$RAPT $29.95 +3.57. SELL/50% of long position/TAKE PROFIT to reduce cost to zero+ https://stocktwits.com/G101SPM/message/622422471
0 · Reply
DylanGFM
DylanGFM Sep. 29 at 9:52 AM
$RAPT it's beautiful 🥲
0 · Reply
DrMoon26
DrMoon26 Sep. 28 at 8:47 AM
$CTMX $LGMK $NVNI $RAPT $RAPT this has way more to go $ANGX added heavily under 4, this will correct sooner then later
2 · Reply
MoonCowBoy
MoonCowBoy Sep. 26 at 9:50 PM
retail running GYRO now! the GYRO Float only 600k could squeeze hard wow $SNSE $RAPT $SMX $UNCY (
0 · Reply